Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.55M | $787K | $1.23M | $2.18M | $231K | $226K | $226K | $226K | $226K | $2.79M |
| Revenue growth | — | -85.8% | 56.0% | 77.8% | -89.4% | -2.2% | 0.0% | 0.0% | 0.0% | 1134.5% |
| Operating income | -$23.7M | -$25.7M | -$23.3M | -$21.7M | -$25.0M | -$16.5M | -$19.6M | -$20.3M | -$142M | -$17.9M |
| Operating margin | -427.4% | -3270.3% | -1895.9% | -994.0% | -10819.5% | -7299.1% | -8684.5% | -8981.4% | -62997.3% | -640.7% |
| Net income | -$19.7M | -$24.1M | -$20.6M | -$21.5M | -$25.2M | -$16.2M | -$19.0M | -$18.9M | -$167M | $9.17M |
| Net margin | -354.6% | -3061.2% | -1675.3% | -985.0% | -10890.5% | -7151.8% | -8391.2% | -8384.1% | -73682.7% | 328.7% |
| EPS (diluted) | -$4.44 | -$40.15 | -$4.99 | -$1.49 | -$2.17 | -$0.96 | -$0.91 | -$22.57 | -$35.21 | $0.82 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.8M | -$23.8M | -$22.7M | -$20.8M | -$23.1M | -$19.5M | -$16.3M | -$17.9M | -$29.8M | -$18.2M |
| Capital expenditures | — | — | — | $55.0K | $15.0K | — | — | $14.0K | $3.65M | $2.58M |
| Free cash flow | — | — | — | -$20.9M | -$23.1M | — | — | -$17.9M | -$33.4M | -$20.8M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $21.4M | $4.02M | $17.0M | $22.7M | $19.0M | $55.1M | $38.8M | $20.8M | $21.3M | $3.82M |
| Total assets | $23.2M | $4.98M | $17.9M | $23.7M | $20.0M | $55.5M | $39.4M | $22.7M | $25.0M | $10.6M |
| Total liabilities | $18.1M | $15.8M | $12.5M | $12.1M | $13.8M | $9.36M | $11.1M | $12.0M | $56.6M | $11.2M |
| Shareholders' equity | $5.13M | -$10.9M | $5.39M | $11.6M | $6.17M | $46.1M | $28.3M | $10.7M | -$31.6M | -$629K |
| Retained earnings | -$338M | -$362M | -$382M | -$403M | -$429M | -$445M | -$464M | -$483M | -$649M | -$640M |
| Shares (wtd avg diluted) | 6.76M | 718K | 5.67M | 111M | 11.6M | 16.8M | 20.9M | 840K | 1.55M | 8.38M |
Every figure is extracted from Traws Pharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.